Figure 3

Outcome of patients with autologous hematopoietic stem cell transplantation for severe autoimmune disease. (a) Probability of survival (n = 414). The 3-year probabilities of survival were 99% ± 3% in 70 rheumatoid arthritis (RA) patients, 92% ± 5% in 150 multiple sclerosis (MS) patients, 84% ± 11% in 51 juvenile idiopathic arthritis (JIA) patients, 79% ± 27% in 10 immune thrombocytopenia (ITP) patients, 72% ± 13% in 71 systemic sclerosis (SSc) patients, and 78% ± 13% in 62 systemic lupus erythematosus (SLE) patients. P = 0.0004 for a global log-rank test. (b) Probability of treatment-related mortality (TRM). The 3-year probabilities of TRM were 2% ± 5% in RA patients, 5% ± 5% in MS patients, 11% ± 10% in JIA patients, 20% ± 25% in ITP patients, 9% ± 7% in SSc patients, and 14% ± 9% in SLE patients. P = 0.24 for a global log-rank test. (c) Probability of death from disease progression. The 3-year probabilities were 20% ± 13% in SSc patients, 0% in RA patients, 7% ± 9% in JIA patients, 16% ± 17% in SLE patients, 2% ± 3% in MS patients, and 0% in ITP patients. P = 0.005 for a global log-rank test. Reprinted with permission from [22]. Copyright 2005, Nature Publishing Group.